Atopic Dermatitis (Atopic Eczema) Drug Development Research Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Atopic Dermatitis (Atopic Eczema) (Dermatology) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
Atopic Dermatitis - Drugs In Development, 2021, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape.
Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.
The publisher's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 57, 37, 4, 81, 28 and 8 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 7 and 3 molecules, respectively.
Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology)
Key Topics Covered:
- Atopic Dermatitis (Atopic Eczema) - Overview
- Atopic Dermatitis (Atopic Eczema) - Therapeutics Development
- Atopic Dermatitis (Atopic Eczema) - Therapeutics Assessment
- Atopic Dermatitis (Atopic Eczema) - Companies Involved in Therapeutics Development
- Atopic Dermatitis (Atopic Eczema) - Drug Profiles
- Atopic Dermatitis (Atopic Eczema) - Dormant Projects
- Atopic Dermatitis (Atopic Eczema) - Discontinued Products
- Atopic Dermatitis (Atopic Eczema) - Product Development Milestones
- 3SBio Inc
- Abate Med Inc
- AbbVie Inc
- Abeome Corp
- Aclaris Therapeutics Inc
- Adare Pharma Solutions
- Akaal Pharma Pty Ltd
- Akeso Inc
- Alexion Pharmaceuticals Inc
- Allergy Therapeutics Plc
- Almirall SA
- Amgen Inc
- Amicogen Inc
- Amorepacific Corp
- Amytrx Therapeutics Inc
- Annji Pharmaceutical Co Ltd
- AOBiome LLC
- Apimeds Inc
- Arcutis Biotherapeutics Inc
- Arena Pharmaceuticals Inc
- Forte Biosciences Inc
- Provectus Biopharmaceuticals Inc
- Pyramid Biosciences Inc
- Qurient Co Ltd
- Ralexar Therapeutics Inc
- RAPT Therapeutics Inc
- Regeneron Pharmaceuticals Inc
- Regeneus Ltd
- Rhizen Pharmaceuticals SA
- Ribomic Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vn5pj8
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900